COMPUGEN LTD (CGEN)       1.01  +0.03 (+3.45%)

1.01  +0.03 (+3.45%)

IL0010852080 - Common Stock

News Image
11 days ago - The Motley Fool

Why Shares of Compugen Jumped 17.86% on Thursday

The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies.

News Image
14 days ago - The Motley Fool

Why Compugen Stock Crumbled Today

Investors indicated their displeasure with the company's recent fundamentals.

News Image
15 days ago - Compugen Ltd.

Compugen Reports Third Quarter 2022 Results

New encouraging preliminary clinical data, presented at SITC 2022, showing anti-tumor activity supported by potent immune activation in the tumor...

News Image
21 days ago - Compugen Ltd.

Compugen to Participate in the Stifel Healthcare Conference

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

News Image
a month ago - Compugen Ltd.

Compugen Announces Receipt of Nasdaq Delisting Notice

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

News Image
a month ago - The Motley Fool

Why Shares of Compugen Jumped 9.27% on Tuesday

The stock's rise came after the company announced when third-quarter earnings will be presented.

News Image
a month ago - Compugen Ltd.

Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

News Image
2 months ago - Compugen Ltd.

Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

News Image
3 months ago - Compugen

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

News Image
3 months ago - InvestorPlace

5 Top Stocks Cathie Wood Sold This Week

August was not a pleasant month for Cathie Wood and ARKK as the ETF experienced outflows of $803 million, the most since last September.

News Image
3 months ago - Compugen Ltd.

Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

News Image
4 months ago - Compugen Ltd.

Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

News Image
4 months ago - Compugen Ltd.

Compugen Reports Second Quarter 2022 Results

Prioritized two indications, MSS-CRC and NSCLC, utilizing fully owned assets, COM701 and COM902 Focus on MSS-CRC and NSCLC expected to provide highest...

News Image
4 months ago - Compugen Ltd.

Compugen to Release Second Quarter Results on Thursday, August 4, 2022

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

News Image
5 months ago - Compugen Ltd.

Compugen to Present at Upcoming Industry Conferences

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...